Adverse effects of GLP – 1 Receptor Agonists

Adverse effects of GLP – 1 Receptor Agonists

Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nau...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2025-02-01
Series:	Journal of Education, Health and Sport
Subjects:	type 2 diabetes obesity, glucagon – like peptide – 1 receptor agonists hypoglycemia gastrointestinal adverse effects nonarteritic anterior ischaemic optic neuropathy
Online Access:	https://apcz.umk.pl/JEHS/article/view/57774
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
by: Fernando K. Malerbi, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
by: Jakob Grauslund, et al.
Published: (2024-12-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

Review: Agonistics. Thinking the World Politically de Chantal Mouffe
by: José Fernández Vega
Published: (2014-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

A Case of Persistent Hypoglycemia: Emphasizing the Role of Kidneys
by: Praveen Govindaraju, et al.
Published: (2024-04-01)

Different post-pancreatectomy glucagon responses to a meal test between surgical approaches
by: Tsuguka Matsuda, et al.
Published: (2023-11-01)

Response to ‘Commentary on the published position statement regarding the pathogenesis of fetal basal ganglia- thalamic hypoxic-ischaemic injury’ (Anthony et al.)
by: I Bhorat, et al.
Published: (2023-12-01)

Hypoglycemia and hospital mortality in critically ill patients
by: Hsuan-Fan Yeh, et al.
Published: (2025-01-01)

Drug resistant epilepsy as the consequence of inadequate control of type 1 diabetes
by: Ewa M. Sokolewicz, et al.
Published: (2024-04-01)

Recurrent nocturnal hypoglycemic hemiplegia: a case report and review of the literature
by: Hanako Toyama, et al.
Published: (2024-04-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
by: Yu‐an Li, et al.
Published: (2025-01-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect
by: Xiyuan Wang, et al.
Published: (2025-01-01)

Profile of STING agonist and inhibitor research: a bibliometric analysis
by: Xuemei Wang, et al.
Published: (2025-02-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist
by: Rahul Brahma, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists
by: E. Sakalauskaitė-Juodeikienė, et al.
Published: (2020-09-01)

Simultaneous cardiocerebral infarctions: a five-year retrospective case series reviewing natural history
by: Cheryl Zhiya Chong, et al.
Published: (2022-11-01)

Stable Stratified Correlation and Linear Negative Correlation Between Serum Albumin and Risk of All-Cause Death in Patients with Ischaemic Stroke
by: Gaihong Xu, et al.
Published: (2024-07-01)

Remdesivir-induced severe hypoglycemia in an elderly man without diabetes: a case report
by: Yasunori Nagano, et al.
Published: (2025-01-01)

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
by: Saixian Shi, et al.
Published: (2025-01-01)

Insulinomas: Comprehensive Review of Epidemiology, Pathophysiology, Clinical Manifestations, Diagnostic Approaches, and Treatment Options
by: Joanna Rychlewska-Duda, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)